GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mapi - Pharma Ltd (NAS:MAPI) » Definitions » Operating Margin %

Mapi - Pharma (Mapi - Pharma) Operating Margin % : 0.00% (As of Jun. 2015)


View and export this data going back to . Start your Free Trial

What is Mapi - Pharma Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Mapi - Pharma's Operating Income for the six months ended in Jun. 2015 was $-2.43 Mil. Mapi - Pharma's Revenue for the six months ended in Jun. 2015 was $0.00 Mil. Therefore, Mapi - Pharma's Operating Margin % for the quarter that ended in Jun. 2015 was 0.00%.

The historical rank and industry rank for Mapi - Pharma's Operating Margin % or its related term are showing as below:


MAPI's Operating Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.09
* Ranked among companies with meaningful Operating Margin % only.

Mapi - Pharma's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Mapi - Pharma's Operating Income for the six months ended in Jun. 2015 was $-2.43 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2015 was $-6.22 Mil.


Mapi - Pharma Operating Margin % Historical Data

The historical data trend for Mapi - Pharma's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mapi - Pharma Operating Margin % Chart

Mapi - Pharma Annual Data
Trend Dec12 Dec13 Dec14
Operating Margin %
- - -

Mapi - Pharma Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15
Operating Margin % - - - - -

Competitive Comparison of Mapi - Pharma's Operating Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Mapi - Pharma's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mapi - Pharma's Operating Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mapi - Pharma's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Mapi - Pharma's Operating Margin % falls into.



Mapi - Pharma Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Mapi - Pharma's Operating Margin % for the fiscal year that ended in Dec. 2014 is calculated as

Operating Margin %=Operating Income (A: Dec. 2014 ) / Revenue (A: Dec. 2014 )
=-7.02 / 0
= %

Mapi - Pharma's Operating Margin % for the quarter that ended in Jun. 2015 is calculated as

Operating Margin %=Operating Income (Q: Jun. 2015 ) / Revenue (Q: Jun. 2015 )
=-2.434 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Mapi - Pharma  (NAS:MAPI) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Mapi - Pharma Operating Margin % Related Terms

Thank you for viewing the detailed overview of Mapi - Pharma's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Mapi - Pharma (Mapi - Pharma) Business Description

Traded in Other Exchanges
N/A
Address
Mapi - Pharma Ltd was incorporated under the laws of the State of Israel on January 29, 2008. It is a development stage pharmaceutical company, engaged in the development of high-barrier to entry and high-added value generic drugs that include complex active pharmaceutical ingredients or APIs, formulations and life cycle management or LCM products that target large markets. The Company is developing two LCM products for the treatment of multiple sclerosis and neuropathic pain. It is also developing a portfolio of approximately 13 complex APIs. Its LCM portfolio focuses on market product, consisting of Glatiramer Acetate Depot, a once-monthly injection for the treatment of MS, Pregabalin ER, extended release capsules for the treatment of neuropathic pain and epilepsy, and Risperidone LAI, a depot formulation of Risperdal Consta, expected to be developed under the abbreviated new drug application ANDA or 505(b)(2) shortened regulatory pathway. Its competitors in the generic pharmaceutical products and LCM markets includes Teva Pharmaceutical Industries Ltd.; Impax Laboratories, Inc.; Alkermes Plc.; Momenta Pharmaceuticals, Inc.; and Andrx Corporation; a private U.S. company. The Company's current patent portfolio contains approximately 20 patent applications for complex APIs, formulations, polymorphs, and routes of synthesis. Its operations are subject to many governmental regulations.

Mapi - Pharma (Mapi - Pharma) Headlines